Production (Stage)
Akebia Therapeutics, Inc.
AKBA
$2.86
$0.031.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.84% | -17.26% | -10.98% | -22.58% | -18.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.84% | -17.26% | -10.98% | -22.58% | -18.49% |
| Cost of Revenue | 200.66% | -9.02% | -39.98% | -4.60% | -76.21% |
| Gross Profit | 64.50% | -18.82% | -2.10% | -26.09% | 4.54% |
| SG&A Expenses | 1.20% | 8.80% | 16.76% | -0.44% | 1.54% |
| Depreciation & Amortization | -- | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.90% | 6.30% | -9.07% | -20.00% | -28.03% |
| Operating Income | 195.72% | -441.88% | 2.81% | 4.02% | 43.20% |
| Income Before Tax | 133.98% | -3,814.01% | -38.30% | 23.18% | 33.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 133.98% | -3,814.01% | -38.30% | 23.18% | 33.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 133.98% | -3,814.01% | -38.30% | 23.18% | 33.08% |
| EBIT | 195.72% | -441.88% | 2.81% | 4.02% | 43.20% |
| EBITDA | 384.78% | -106.10% | 9.51% | 116.09% | 68.80% |
| EPS Basic | 129.61% | -3,359.38% | -23.93% | 31.61% | 39.66% |
| Normalized Basic EPS | 132.55% | -837.50% | -25.26% | 28.69% | 42.62% |
| EPS Diluted | 128.89% | -3,359.38% | -23.93% | 31.61% | 38.14% |
| Normalized Diluted EPS | 131.58% | -837.50% | -25.26% | 28.69% | 42.62% |
| Average Basic Shares Outstanding | 14.90% | 15.16% | 11.71% | 12.25% | 10.93% |
| Average Diluted Shares Outstanding | 17.88% | 14.80% | 11.71% | 12.25% | 10.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |